CompletedNCT00823199

Allopurinol added for schizophrenia that responds poorly to treatment

About this title

Researchers studied Allopurinal to find out how it affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18–65

The study in practice

Understand this study

Researchers studied Allopurinal to find out how it affected psychotic symptoms in people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Study clarity

Study start dateNovember 2005

Recruitment status: Completed
Enrollment listed in the registry: 10
Sponsor: Bronx Psychiatric Center
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: Not clearly listed
Age range: From 18 Years to 65 Years
Official registry ID: NCT00823199
Official title: Show the full official title
An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

Completed

Locations not listed

FAQ

What did researchers investigate?

Researchers studied Allopurinal to find out how it affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Bronx Psychiatric Center.

Did this study involve medication?

Yes. The study involved medication, including Allopurinal.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.